8 completed, 6 active not recruiting, 4 terminated. 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 8, Active not recruiting 6, Terminated 4 |
Follow avelumab: new trials by email Literature Review of avelumab trials Research Report on avelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-26 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Avelumab, Lorlatanib, Talazoparib - Advanced Malignancies, NSCLC | Phase 3 | Active not recruiting | Pfizer | 77 | 2021-09-29 | 2026-10-20 |
| Avelumab Program Rollover Study Avelumab - Solid Tumors | Phase 3 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 205 | 2019-03-22 | 2026-09-22 |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer Avelumab - POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability | Phase 3 | Terminated | Royal Marsden NHS Foundation Trust | 30 | 2018-08-31 | 2022-10-07 |
| Adjuvant Avelumab in Merkel Cell Cancer Avelumab, Peripheral Blood Collection, Placebo - Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | University of Washington | 101 | 2017-12-19 | 2026-06-15 |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Cetuximab, avelumab, Cisplatin - HNSCC | Phase 3 | Active not recruiting | Groupe Oncologie Radiotherapie Tete et Cou | 707 | 2017-09-14 | 2026-10-02 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | Pfizer | 29 | 2016-12-16 | 2020-12-17 |
| Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Avelumab, Chemoradiation - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Pfizer | 697 | 2016-11-28 | 2021-09-22 |
| Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab MSB0010718C - Triple Negative Breast Neoplasms | Phase 3 | Completed | Istituto Oncologico Veneto IRCCS | 474 | 2016-06-17 | 2025-12-12 |
| Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) carboplatin, paclitaxel, Avelumab - Ovarian Cancer | Phase 3 | Terminated | Pfizer | 998 | 2016-05-19 | 2020-07-14 |
| A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab - Urothelial Cancer | Phase 3 | Completed | Pfizer | 700 | 2016-04-25 | 2024-03-27 |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib - Renal Cell Cancer | Phase 3 | Completed | Pfizer | 886 | 2016-03-23 | 2025-07-30 |
| Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Avelumab, Irinotecan, Paclitaxel - Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 371 | 2015-12-28 | 2020-11-24 |
| Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Avelumab, Oxaliplatin, 5-Fluorouracil - Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 499 | 2015-12-24 | 2022-06-09 |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) avelumab, PLD - Ovarian Cancer | Phase 3 | Completed | Pfizer | 566 | 2015-12-21 | 2023-07-10 |
| Avelumab in First-line NSCLC (JAVELIN Lung 100) Avelumab, Pemetrexed, Paclitaxel - First Line Non-Small Cell Lung Cancer | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 1214 | 2015-10-29 | 2025-01-31 |
| Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Avelumab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | EMD Serono Research & Development Institute, Inc. | 792 | 2015-03-24 | 2020-08-03 |
Ovarian Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Merkel Cell (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Microsatellite Instability (1) · Neoplasm Metastasis (1)
Pfizer (7) · EMD Serono Research & Development Institute, Inc. (5) · Alliance for Clinical Trials in Oncology (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Istituto Oncologico Veneto IRCCS (1) · National Cancer Institute (NCI) (1) · Royal Marsden NHS Foundation Trust (1) · University of Washington (1)
United States (15) · Italy (13) · United Kingdom (13) · South Korea (12) · Australia (11) · France (11) · Spain (11) · Belgium (10) · Hungary (10) · Japan (10) · Poland (10) · Russia (10) · Canada (9) · Taiwan (8) · Germany (7)
Bradley Monk, MD (1) · Jonathan Ledermann, MD (1) · Shailender Bhatia (1) · Shilpa Gupta (1) · Tony Dhillon, Bsc,FRCP, PhD (1) · Valentina Guarneri, Prof (1) · Xiao X. Wei, MD, MAS (1)
PMID 30052729, PMID 30262187, PMID 30779531, PMID 32079623, PMID 32339648, PMID 32895571, PMID 32945632, PMID 33125944, PMID 33197226, PMID 33636453, PMID 33794205, PMID 33901870, PMID 33947608, PMID 34143970, PMID 34363762, PMID 34687398, PMID 34893775, PMID 34973108, PMID 35144482, PMID 35166465, PMID 35239416, PMID 35416053, PMID 35623069, PMID 35654659, PMID 35771392, PMID 37019764, PMID 37071838, PMID 37104931, PMID 37121850, PMID 37146227, PMID 37149458, PMID 37407274, PMID 37526095, PMID 37665777, PMID 37748693, PMID 37852850, PMID 37884606, PMID 38728337, PMID 39706335, PMID 39886142
2015 (7), 2016 (3), U10CA180821 (2), 2014 (1), 2018 (1), 2023 (1)